Nasdaq · CIK 0000872589 · PHARMACEUTICAL PREPARATIONS
REGENERON PHARMACEUTICALS, INC.
REGN chart by TradingView
PRICE HISTORY
LIVE · NASDAQREGN chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $14.3B
- EBITDA
- $4.1B
- FREE CASH FLOW
- $4.1B
- EPS
- $41.48
- GROSS MARGIN
- —
- ROIC
- 14.95%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
15.3x
-74%8.9x58.7x
⤢
P / SALES (TTM)
4.3x
-57%4.0x10.9x
⤢
P / BOOK
2.1x
-80%1.9x10.4x
⤢
EV / EBITDA (TTM)
15.0x
-22%7.7x27.8x
⤢
EV / REVENUE (TTM)
4.2x
-48%4.0x9.0x
⤢
FCF YIELD (TTM)
5.69%
+3.9pp1.56%11.68%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$4.3B
+252%⤢
EBITDA (DERIVED)
$1.4B
+263%⤢
NET INCOME
$1.3B
+390%⤢
EPS (DILUTED)
$12.23
+438%⤢
REVENUE GROWTH YOY
16.73%
+9.5pp-77.09%413.93%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
13.35%
-30.3pp-17.76%177.41%
⤢
RETURN ON CAPITAL
13.86%
-16.1pp13.86%45.21%
⤢
RETURN ON EQUITY (TTM)
13.65%
-4.1pp13.65%43.03%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN30.15%
NET MARGIN30.23%
FCF MARGIN13.35%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.6B
+8%⤢
STOCK-BASED COMP
$0.2B
+85%⤢
CAPITAL EXPENDITURE
$0.2B
+103%⤢
SHARES OUTSTANDING
0.11B
-9%⤢
DIVIDEND / SHARE
$0.94
+7%BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$2.5B
+167%⤢
TOTAL DEBT
$2.0B
+0%⤢
DEBT / EBITDA (TTM)
0.5x
-24%0.2x0.6x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 94.70%INSIDERS 2.08%OTHER / RETAIL 3.22%1,930 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 8.85% | 8.9M | $7.02B | +2.4% |
| Vanguard Capital Management LLC | 6.58% | 6.7M | $5.22B | NEW |
| State Street Corporation | 4.61% | 4.7M | $3.66B | +0.1% |
| Dodge & Cox Inc. | 4.41% | 4.5M | $3.50B | -3.0% |
| JPMORGAN CHASE & CO | 4.26% | 4.3M | $3.38B | +9.4% |
| Invesco Ltd. | 3.86% | 3.9M | $3.06B | -0.2% |
| Franklin Resources, Inc. | 2.69% | 2.7M | $2.14B | +6.3% |
| Geode Capital Management, LLC | 2.58% | 2.6M | $2.05B | +3.5% |
| Price (T.Rowe) Associates Inc | 2.15% | 2.2M | $1.71B | +11.7% |
| Nuveen, LLC | 2.04% | 2.1M | $1.62B | +2.7% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.